Nuvalent Past Earnings Performance
Past criteria checks 0/6
Nuvalent's earnings have been declining at an average annual rate of -50.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-50.3%
Earnings growth rate
48.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -18.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22
Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?
Jan 07Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
Sep 23Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Jun 10We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow
Feb 24Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Sep 13Nuvalent GAAP EPS of -$0.38 beats by $0.03
Aug 10Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
May 28We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Oct 29Revenue & Expenses BreakdownBeta
How Nuvalent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -126 | 36 | 113 |
| 30 Sep 23 | 0 | -114 | 32 | 101 |
| 30 Jun 23 | 0 | -100 | 28 | 86 |
| 31 Mar 23 | 0 | -89 | 25 | 73 |
| 31 Dec 22 | 0 | -82 | 22 | 64 |
| 30 Sep 22 | 0 | -73 | 20 | 54 |
| 30 Jun 22 | 0 | -66 | 18 | 49 |
| 31 Mar 22 | 0 | -57 | 15 | 43 |
| 31 Dec 21 | 0 | -46 | 10 | 36 |
| 30 Sep 21 | 0 | -36 | 7 | 27 |
| 30 Jun 21 | 0 | -28 | 4 | 22 |
| 31 Mar 21 | 0 | -27 | 2 | 18 |
| 31 Dec 20 | 0 | -15 | 2 | 15 |
Quality Earnings: NUVL is currently unprofitable.
Growing Profit Margin: NUVL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NUVL is unprofitable, and losses have increased over the past 5 years at a rate of 50.3% per year.
Accelerating Growth: Unable to compare NUVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: NUVL has a negative Return on Equity (-18.02%), as it is currently unprofitable.